On Wednesday, shares of biopharmaceutical company Repros Therapeutics Inc RPRX are soaring around 30% in late-morning trading after the company reported after Tuesday’s close positive drug study results. According to a small Phase 2b study, patients receiving 6mg and 12mg doses of Proellex saw significant reduction in excessive menstrual bleeding, which is a key symptom of uterine fibroids; the drug was generally well tolerated. Repros believes Prollex "represents a significant advantage over GnRH agonists and antagonists in the treatment of uterine fibroids." The company plans on requesting an end of Phase 2 after meeting with the U.S. Food and Drug Administration, and will discuss plans for a Phase 3 trial. RPRX currently has a #1 (Strong Buy) on the Zacks Rank. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report To read this article on Zacks.com click here. Zacks Investment Research